|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,540.00 JPY | +2.12% |
|
+0.49% | +14.58% |
| 08-06 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-06 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 5,890 | 5,890 | 5,840 |
| Spread/Res. | -5.94% | -5.94% | -5.14% |
| Spread/Supp. | +9.62% | +16.68% | +33.40% |
| Support | 5,054 | 4,748 | 4,153 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- 4502 Stock
- Charts Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
